Showing results (1-10 of 345) with videos related to
Sort By:
Pageof 35
The Journal of Clinical Psychiatry|June 26, 2003
Chlorpromazine equivalent doses for the newer atypical antipsychoticsScott W WoodsDepression and Anxiety|February 11, 2003
Is there a SSRI dose response in treating major depression? The case for re-analysis of current data and for enhancing future study designC Bruce Baker, Scott W WoodsChild and Adolescent Psychiatric Clinics of North America|December 3, 2005
The schizophrenia prodrome: a developmentally informed review and update for psychopharmacologic treatmentLynelle E Thomas, Scott W WoodsCNS Drugs|March 3, 2005
Prevention of schizophrenia: can it be achieved?Cheng Lee, Thomas H McGlashan, Scott W WoodsCommunity Mental Health Journal|September 6, 2005
Effects of ethnicity on psychotropic medications adherenceEsperanza Diaz, Scott W Woods, Robert A RosenheckJournal of Clinical Psychopharmacology|April 30, 2022
Prescription Stimulants and the Risk of Psychosis: A Systematic Review of Observational StudiesKeith E Gallagher, Melissa C Funaro, Scott W WoodsGeneral Hospital Psychiatry|May 4, 2004
Mood-stabilizer-maintained, remitted bipolar patients: taper and discontinuation of adjunctive antipsychotic medicationJohn R Saksa, C Bruce Baker, Scott W WoodsPsychosis|May 14, 2011
DSM-5 and the 'Psychosis Risk Syndrome': The DSM-5 proposal is better than DSM-IVScott W Woods, Jon P Carlson, Thomas H McGlashanPsychiatric Services (Washington, D.C.)|November 3, 2009
Multifamily psychoeducation for first-episode psychosis: a cost-effectiveness analysisNicholas J K Breitborde, Scott W Woods, Vinod H SrihariDepression and Anxiety|February 11, 2003
Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysisC Bruce Baker, Richard Tweedie, Sue Duval, et al.Pageof 35